FDA Sniffs Asthma Drugs Over Child Safety Concerns
Safety officials at the Food and Drug Administration will meet this week to discuss the rare, but potentially fatal, side effects of GlaxoSmithKline Plc's top-selling asthma drugs Serevent and Advair in...To view the full article, register now.
Already a subscriber? Click here to view full article